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Background: Mice models indicate that intact Toll like receptor (TLR) signaling may be essential for the allergy
protective effects of diverse bacterial exposure observed in clinical trials and epidemiological studies. Probiotic
supplementation with Lactobacillus reuteri from pregnancy week 36 and to the infant through the first year of life
decreased the prevalence of IgE-associated eczema at two years (ClinicalTrials.gov NCT01285830). The effect of this
supplementation on innate immune responses to bacterial products and the expression of associated TLRs were
explored.
Methods: Blood mononuclear cells were collected at birth, 6, 12 and 24 months from 61 infants and cultured with
TLR2, 4 and 9 ligands. Cytokine and chemokine secretion was determined as well as TLR2, 4 and 9 mRNA
expression.
Results: Probiotic supplementation was associated with decreased LTA (lipoteichoic acid) induced CCL4, CXCL8,
IL-1β and IL-6 responses at 12 months and decreased CCL4 and IL-1β secretion at 24 months. TLR2 mRNA
expression was not affected by probiotic treatment.
Conclusions: Decreased responses to TLR2, the main receptor for LTA from Gram positive bacteria, in probiotic
treated children seem to be dependent on factors downstream of TLR mRNA expression.
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Microbial exposure in early life educates the developing im-
mune system, driving postnatal maturation of immune
regulation [1]. The main receptors for bacterial products
are the Toll like receptors (TLRs), which seem to be essen-
tial for the allergy protective effect of bacterial exposure
during pregnancy [2].
Several studies have shown a lower incidence of ec-
zema after probiotic supplementation pre- and postna-
tally, whereas prenatal or postnatal supplementation
only have not generally been successful [3,4]. The
underlying mechanisms of the allergy preventive effects
are unclear, however. While probiotic supplementation
may modulate adaptive immunity in infants [5-10], the
effects on innate immune responses at the cellular level
in infants are unknown. In one cohort showing that* Correspondence: anna.forsberg@liu.se
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unless otherwise stated.postnatal probiotic supplementation during the first six
months of life had no clinical effect [11], no differences
in innate immune responses were observed [12].
Previously, Lactobacillus reuteri supplementation in a
randomized placebo controlled trial reduced IgE-associated
eczema at the age of two years [13] but showed no protect-
ive effect on asthma development at the age of seven
[14]. Infants supplemented with probiotics showed lower
secretion of Th1/Th2 and anti-inflammatory cytokines and
chemokines after allergen and mitogen stimulation as
compared with infants receiving placebo [10]. These results
suggest that Lactobacillus reuteri supplementation could
enhance the immune regulatory capacity during infancy,
possibly via innate-mediated mechanisms. This prompted
us to investigate if the pre- and postnatal supplementation
with Lactobacillus reuteri affects the innate cytokine and
chemokine responses to bacterial products (the TLR2 lig-
and lipoteichoic acid (LTA) [15,16], the TLR4 ligand lipo-
polysaccharide (LPS) [17] and the TLR9 ligand CpG [18]),
as well as expression of the associated receptors.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study design
Sixty-one children, of whom 29 received probiotics and 32
placebo (Table 1), were selected based on availability of
blood cell samples at multiple time points from a double-
blind, randomized, placebo-controlled probiotic trial, in
which 188 infants completed the study, ClinicalTrials.gov,
NCT01285830 [13]. The infants included in this study had
cells collected from at least three time points, i.e. birth, 6,






Boys 55 (16/29) 50 (16/32) 0.82
First born 55 (16/29) 63 (20/32) 0.77
Caesarean delivery 14 (4/29) 3 (1/32) 0.16
Birth weight (g)
(mean ± SE)
3656 ± 434 3469 ± 429 0.10*
Birth length (cm) 51.3 ± 2.0 50.6 ± 1.9 0.18*
Parental smoking 10 (3/29) 9 (3/32) 0.91
Furry pets 7 (2/29) 13 (4/32) 0.51
Maternal atopy 79 (23/29) 75 (24/32) 0.89
Paternal atopy 62 (18/29) 69 (22/32) 0.80
Breastfeeding
3 months, exclusive 59 (17/29) 78 (23/32) 0.62
6 months, partial 83 (24/29) 78 (24/32) 0.80
Antibiotics
0–12 months 34 (10/29) 16 (5/32) 0.18
12–24 months 48 (14/29) 53 (17/32) 0.83
Day-care
0–12 months 0 (0/29) 3 (1/32) 0.35
12–24 months 86 (25/29) 94 (30/32) 0.82
Recurrent wheeze 3 (1/29) 6 (2/32) 0.63
Eczema 28 (8/29) 28 (9/32) 0.97
Allergic disease 34 (10/29) 38 (12/32) 0.87
Sensitisation 38 (11/29) 34 (11/32) 0.84
IgE-assoc. Disease 10 (3/29) 16 (5/32) 0.59
SPT (12 m cumulative) 10 (3/29) 16 (5/32) 0.37
SPT (24 m cumulative) 17 (5/29) 16 (5/32) 0.89
Egg 10 (3/29) 13 (4/32) 0.81
Milk 3 (1/29) 0 (0/32) 0.30
Cat 3 (1/29) 6 (2/32) 0.63
Birch 3 (1/29) 3 (1/32) 0.95
Spec IgE (kU/L) 34 (10/29) 31 (10/32) 0.85
Ovalbumin 7 (2/29) 22 (7/32) 0.15
b-lactoglobulin 24 (7/29) 9 (3/32) 0.19
fx5 31 (9/29) 28 (9/32) 0.85
X 2 test. *t-test.different from the main trial with regards to the variables
presented in Table 1. They all had a family history of aller-
gic disease, i.e. at least one family member had eczema,
asthma, gastrointestinal allergy, allergic urticaria, and/or al-
lergic rhinoconjunctivitis. The pregnant women either re-
ceived Lactobacillus reuteri ATCC 55730 or placebo daily
from week 36 until delivery, and their infants continued
from day 1–3 with the same product daily until 12 months
of age. An informed consent was obtained from both par-
ents before inclusion.
The Lactobacillus preparation consisted of freeze-dried L.
reuteri suspended in coconut oil and peanut oil containing
cryoprotective components, while the placebo preparation
only comprised the vehicle. The daily intake corresponded
to 1 × 108 colony forming units (CFUs).
The children were monitored by research nurses and a
final follow up was done by a pediatrician at 2 years of age,
i.e. one year after the termination of treatment. Skin prick
tests (SPTs) were done at 6, 12 and 24 months of age. Po-
tentially allergic disease included eczema, recurrent wheeze,
rhinoconjunctitivis, urticaria and gastrointestinal allergy.
Eczema was classified as a pruritic, chronic, or chronically
relapsing non-infectious dermatitis with typical features
and distribution. Eczema was classified as IgE-associated if
the infant was also sensitized, i.e. had at least one positive
SPT and/or detectable circulating IgE antibodies to aller-
gens. Wheeze was defined as an episode with obstructive
airway symptoms, and recurrent wheeze was defined as
three or more wheezing episodes, at least once verified by a
physician. Allergy was defined as having at least one posi-
tive SPT and/or detectable circulating IgE (>0.35 kU/L), in
addition to clinical symptoms consistent with eczema or re-
current wheeze. The eight children defined as allergic
in this study all had IgE-associated eczema (n = 3 L. reuteri/
n = 5 placebo). One child also had recurrent wheeze, one
child allergic urticaria and one gastrointestinal allergy, while
none of the children had allergic rhinoconjunctivitis. Non-
sensitized children with symptoms (n = 8) and sensitized
children without symptoms (n = 14) were not included in
the analysis comparing allergic and non-allergic children. In
the main trial, the prevalence of IgE-associated eczema at
two years was lower in the L reuteri than the placebo group
(8% vs. 21%, p = 0.02) [13].
Ethics statement
This study was approved by the Regional Ethics Committee
for Human Research at Linköping University (Dnr 99323)
and registered at ClinicalTrials.gov (NCT01285830).
Sample preparations
Cord blood was collected at birth and venous blood
samples were drawn at 6, 12 and 24 months into hepa-
rinized vacutainers. Peripheral blood mononuclear cells
(PBMC) were collected by Ficoll gradient centrifugation.
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fuged and the PBMC layer was collected with subse-
quently washing and centrifugation steps. Cells were
resuspended in freezing media consisting of 40% IMDM,
10% DMSO and 50% FCS. The cells were then placed in
a freezing container at −70°C for 24 hours and thereafter
stored in liquid nitrogen, pending analysis [19].
Cell cultures stimulated with TLR ligands
PBMCs were thawed and stimulated with 1 ng/ml lipo-
teichoic acid (LTA) from S. aureus (InvivoGen, San
Diego, USA), 1 ng/mL lipopolysaccharide (LPS) from E.
coli K12 (Invivogen) or 1 μg/ml CpG ODN M362 (Invi-
voGen) in AIM V (Life Technologies AB, Täby, Sweden)
with 20 μM mercaptoethanol (Sigma-Aldrich) at a con-
centration of 1 × 106/ml and incubated for 24 hours at
37°C. Unfortunately, enough cells were not always avail-
able for all stimuli. Cell cultures were then centrifuged,
supernatants were collected and cell pellets were lysed
in RLT-buffer (Qiagen GmbH, Hilden, Germany) and
stored at −70°C for later mRNA analysis. The mean via-
bility of the freeze/thawed PBMCs was 85.2%.
RNA extraction and quantitative real time PCR
determination TLR2/4 and 9 mRNA and 18S rRNA
Total RNA was extracted from the control/spontaneous
RLT-lysates using the RNeasy 96 plate-kit (Qiagen GmbH),
according to the manufacturer’s instructions. Real-time
PCR was conducted, as described previously [10]. Briefly,
1 μL of cDNA was mixed with 19 μL TaqMan Fast Univer-
sal Mastermix (Applied Biosystems, Paisley, UK) together
with primers and probe for TLR2 mRNA (HS001529
32_m1), TLR4 mRNA (HS01060206_m1), TLR9 mRNA
(HS00370913_s1) (Applied Biosystems). The sequences for
18S rRNA primers and probe (Eurogentec S.A, Seraing,
Belgium) have been described elsewhere [20].
Measurement of cytokine and chemokine secretion by
Luminex
The levels of pro-inflammatory cytokines and chemokines
(IL-1β, IL-6, IL12p70, IFN-a, TNF, CCL4 and CXCL8) and
the anti-inflammatory cytokine IL-10 in the cell superna-
tants were analysed with multiplex assay kits, according to
the manufacturer’s instructions (Bio-Rad Laboratories,
Hercules, CA, USA). The samples were analysed on a
Luminex100 instrument (Biosource, Nivelles, Belgium) and
the data was analysed with the software StarStation 2.0
(Applied Cytometry Systems, Sheffield, UK). The lower de-
tection limit was 2,34 pg/mL for IL-1β, 33 pg/mL for IL-6,
1 pg/mL for IL-10, 0.5 pg/mL for IL12p70, 10 pg/mL for
IFN-α, 20 pg/mL for CCL4 and CXCL8 and 3 pg/mL for
TNF. Undetectable samples were given the value of half the
cut off level. Comparisons of the TLR ligand induced cyto-
kine and chemokine responses were made after the controlvalue, i.e. responses from cells cultured in medium alone,
was withdrawn. Detectable levels of IL-6, IL-10, CCL4,
CXCL8 and TNF could be measured after all stimulations.
After LPS and LTA stimulation, IL-1β levels could also be
detected. Detectable IFN-α levels were observed only after
stimulation with CpG.
Statistics
As the data were not normally distributed, non-parametric
tests were used. Comparisons between unpaired groups
were analyzed with Mann–Whitney U-test, and correla-
tions were analyzed with Spearman’s rank order correlation
coefficient test. The student’s t-test and χ2-test was used to
compare the background factors between the groups. Pro-
biotic supplementation was included as dependent variable
(placebo coded as 1, probiotic as 0) and IgE-associated
allergic disease was included as independent variable in
a logistic regression model, and the association between
cytokine and chemokine secretion and these variables was
investigated. P-values <0.05 were considered statistically
significant. Calculations were performed with a SPSS statis-
tical package version 19.0; SPSS Inc, Chicago, Ill. Undetect-
able samples were given the value of half the cutoff.
Results
Probiotic supplementation is associated with a reduced
TLR2 ligand induced secretion of IL-1β, IL-6, CCL4 and
CXCL8
The levels of the chemokines CCL4 and CXCL8 were
lower after stimulation with the TLR2 ligand LTA at
12 months in the probiotic than the placebo group
(p = 0.014 and p = 0.043, respectively, Figure 1) and for
CCL4 also at 24 months (p = 0.048, Figure 1). Furthermore,
probiotic supplementation was associated with low levels
of the pro-inflammatory cytokines IL-1β and IL-6 after
LTA stimulation at 12 months (p = 0.002 and p = 0.017,
respectively) and for IL-1β (p = 0.014) at 24 months. The
cytokine and chemokine responses to LTA were statistically
significantly lower at several time-points and showed
similar trends at all ages in the probiotic compared with
the placebo treated infants. Other measured cytokines
showed no difference (Additional file 1: Table S1).
Although the probiotic treated infants showed the most
clear and consistent differences in TLR2 responsiveness,
probiotic supplementation was also associated with low
CXCL8 responses to the TLR4 ligand LPS at birth
(p = 0.040). No further differences were observed in
responsiveness to TLR4 and TLR9 ligation (Additional
file 1: Table S1).
TLR mRNA expression in Lactobacillus reuteri and placebo
supplemented infants
Since exposure to a farm environment has been sug-
gested to up-regulate TLR mRNA expression [16-18], we
Figure 1 LTA induced responses. LTA induced IL-1β (A), IL-6 (B), CCL4 (C), CXCL8 (D), responses from peripheral blood mononuclear cells during the
two first years in life in probiotic (filled squares) and placebo (open circles) treated children. Groups were compared using Mann–Whitney U-test,
**p < 0.01, *p < 0.05. The number of analyzed samples is indicated (n), as well as the median values.
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mRNA expression of TLR2/4 or 9. Neither the TLR2
nor the TLR9 expression differed between the two
groups (Additional file 1: Table S1). The mRNA expres-
sion of TLR4 was significantly lower in the probiotic
group than in the placebo group at 6 months of age,
however (p = 0.039, Figure 2).
TLR ligand induced cytokine and chemokine responses in
allergic and non-allergic children
No major differences in TLR ligand induced cytokine
and chemokine responses were found between allergic
(n = 3 L. reuteri/n = 5 placebo) and non-allergic children
(n = 13 L. reuteri/n = 16 placebo) (Additional file 2: Table
S2). Allergic infants secreted higher LPS-induced IL-1β
levels at 6 months than non-allergic infants (p = 0.042)
and lower CpG-induced TNF levels at 24 months (p =
0.048), however. TLR2 mRNA expression was higher at
12 months in non-allergic than allergic children (p =
0.021, Figure 3).
TLR ligand induced cytokine and chemokine responses
are associated with probiotic treatment independently of
allergy development
Logistic regression analyses were performed to evaluate
whether the relationship between cytokine responses was
dependent on a parallel association with allergic disease.Probiotic supplementation and IgE-associated allergic dis-
ease were included in the model in order to control for po-
tential confounding, whereas maternal or double atopic
heredity were not, since these variables had no effect.
Adjusting for allergy development had no major effect on
the association between probiotic treatment and cytokine
responses in this model (Additional file 3: Table S3).
Correlation between TLR mRNA expression and TLR
responsiveness
The TLR4 mRNA levels correlated with LPS induced cyto-
kine and chemokine levels at the corresponding age in cord
blood (CXCL8, p = 0.022, rho = 0.40) and at 24 months
(TNF, CCL4, CXCL8, IL-1β, p < 0.001-0.04, rho = 0.35–
0.66). At 6 months TLR9 mRNA expression correlated with
CpG induced IL-10, IFNα, TNF, CCL4 (p < 0.001–0.01,
rho = 0.40–0.51). TLR2 mRNA expression did only correl-
ate at one time point with LTA induced cytokine and che-
mokine expression, (IL-10, 6 months, p = 0.011, rho = 0.34).
Discussion
Pre- and postnatal supplementation with the Gram-
positive probiotic bacterium Lactobacillus reuteri de-
creased TLR2 ligand induced proinflammatory cytokine
and chemokine responses. The lower IL-1β, IL-6, CCL4
and CXCL8 responses to TLR2 stimulation in the pro-
biotic treated infants were not dependent on differences
Figure 2 TLR4 mRNA expression. Comparison of TLR4 mRNA
expression of peripheral blood mononuclear cells during the two
first years in life in probiotic (filled squares) and placebo (open
circles) treated children. The values represent TLR4/18S expression
ratios. Groups were compared using Mann–Whitney U-test, *p < 0.05.
The number of analysed samples is indicated (n), as well as the
median values.
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group. Probiotic supplementation may be associated with
an increased immune regulatory capacity during infancy, in
line with our previous findings showing lower allergen re-
sponsiveness in the probiotic treated children [10].
Microbial stimulation is suggested for normal develop-
ment of immune regulatory capacity [3,21]. The probiotic
supplementation could then provide a source of TLR ligand
exposure [3,21,22]. The lower responses to TLR2 stimula-
tion could be dependent on an induction of regulatoryFigure 3 TLR2 mRNA expression. Comparison of TLR2 mRNA
expression of peripheral blood mononuclear cells during the two
first years in life in non-allergic (open triangles) and allergic children
(filled circles). The values represent TLR2/18S expression ratios.
Groups were compared using Mann–Whitney U-test, *p < 0.05. The
number of analysed samples is indicated (n), as well as the
median values.macrophages responding to stimuli with lower secretion of
pro-inflammatory cytokines and chemokines [23], as
well as an induction of Tregs [24,25] which could be
strain dependent [26]. Notably, induction of the anti-
inflammatory cytokine IL-10 was not reduced by pro-
biotic supplementation. Possibly, lower responses to
TLR2 stimulation could be due to a phenomenon called
lipoteichoic acid tolerance, which does not involve
TLR2 expression but is dependent on a downstream ef-
fect involving IRAK [27]. Our data do indicate that the
TLR2 mRNA expression and LTA induced cytokine and
chemokine responses are not correlated.
Whether this down-regulation of TLR2 responses is also
related to the decreased incidence of IgE-associated disease
in probiotic treated children is unclear. Other studies sug-
gest differences in TLR responsiveness between children
who do and do not develop allergy [28-30]. While TLR lig-
and stimulation resulted in exaggerated responses at birth
in children later developing allergy [29], these responses
later seem to be attenuated in allergic compared to non-
allergic children at the age of five years [28,30]. The number
of allergic infants was probably too low to discriminate a
significant and consistent difference in our study, although
we did detect higher levels of TLR2 mRNA expression in
non-allergic than allergic infants at one time point,
12 months of age. Anyway, the logistic regression analyses
suggested that the effects of probiotic supplementation on
TLR2 responsiveness were independent of allergy develop-
ment in this study. Also, important to acknowledge was
that there were no differences in antibiotic use and infec-
tions between probiotic and placebo treated infants which
suggest that lower responses to TLR2 ligands is not detri-
mental in the protection against pathogens.
That probiotic supplementation may be associated
with an increased immune regulatory capacity during in-
fancy is also in line with studies suggesting that immune
regulatory mechanisms are established at a later age in
Sweden compared to Estonia [31], a country with higher
microbial exposure and lower allergy prevalence than
Sweden [32]. Estonian infants responded with lower
levels of cytokines, both adaptive and innate, after aller-
gen stimulation [31] and LPS stimulation, respectively,
than Swedish infants. In concordance, neonatal antigen
presenting cells are more quiescent in children born
under traditional, i.e. Papua New Guinea, compared to
modern environmental conditions, i.e. Australia [33].
This quiescent function could potentially be a protective
mechanism learned in utero and associated with an en-
hanced immune regulatory capacity among infants living
in conditions with a higher microbial burden.
Conclusion
Decreased responses to TLR2, the main receptor for
LTA from Gram positive bacteria, in probiotic treated
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of TLR mRNA expression.
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chemokine (pg/ml) responses and TLR2 and −9 mRNA expression (TLR/
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Additional file 2: Table S2. TLR-ligand induced cytokine and
chemokine responses (pg/ml) in allergic and non-allergic infants. Median,
1st and 4th quartile values are indicated.
Additional file 3: Table S3. Cytokine and chemokine responses after
probiotic supplementation adjusted for IgE-associated allergic disease.
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